Showing results (291-300 of 322) with videos related to

Sort By:
Pageof 33
Haematologica|May 14, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, et al.
Blood Cancer Journal|March 6, 2026
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemiaNiccolò Bartalucci, Francesco Mannelli, Danilo Tarantino, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Blood Advances|March 5, 2021
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosisSebastiano Rontauroli, Sara Castellano, Paola Guglielmelli, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
American Journal of Hematology|June 15, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trialBianca Rocca, Alberto Tosetto, Giovanna Petrucci, et al.
Blood Cancer Journal|June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical settingValerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
American Journal of Human Genetics|January 9, 2021
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosisGabriella Galatà, Andrés C García-Montero, Thomas Kristensen, et al.
Pageof 33